Kodiak Sciences stock gets closer to a BLA after DAYBREAK data

Published on 10/05/2026 at 10:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kodiak Sciences reported 54 percent six-month dosing in its September 28, 2026, DAYBREAK study. Q2 net loss reached USD 65.64 million.

KOD, US50015M1099, Illustration mit AI erstellt.

Kodiak Sciences stock (ISIN US50015M1099) closed at USD 94.45 on Nasdaq on October 2, 2026, down 4.07 percent from the prior session. The central development came on September 28, 2026, when Kodiak Sciences reported that Zenkuda and tabirafusp-ted met primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration.

DAYBREAK delivers a measurable result

Zenkuda achieved non-inferior vision gains against aflibercept at one year, while 54 percent of patients reached a six-month dosing interval under strict treat-to-dryness retreatment criteria. Tabirafusp-ted also met its vision primary endpoint, with a p-value of 0.0036, and its anatomical key secondary endpoint, with a p-value below 0.0001, according to Kodiak Sciences.

The safety comparison also favored a clear numerical reading. Zenkuda recorded a 0.5 percent cataract adverse event rate versus 0.9 percent for aflibercept, while intraocular inflammation was 0 percent for Zenkuda and 0.4 percent for tabirafusp-ted.

A BLA path meets a cash question

Kodiak plans to submit a multi-indication biologics license application for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion. The company also expects topline Phase 3 data for KSI-101 in December 2026, creating a second clinical checkpoint after the DAYBREAK result.

The financial base remains that of a precommercial biotechnology company. For Q2 2026, Stock Analysis lists a net loss of USD 65.64 million and earnings per share of negative USD 1.05, while cash and equivalents stood at USD 125.90 million. The Q2 loss per share was USD 0.09 below the cited consensus estimate of negative USD 0.96.

Analysts see a wide valuation spread

Investing.com reports a Strong Buy consensus from 6 analysts, with an average 12-month price target of USD 116.667, a high of USD 145 and a low of USD 96. The average target stands 23.52 percent above the October 2 price of USD 94.45.

Recent individual views are less uniform. MarketBeat reports that UBS raised its target from USD 80.00 to USD 120.00 on September 28, 2026, while H.C. Wainwright lifted its target from USD 58.00 to USD 96.00. Goldman Sachs carries a Neutral rating with a USD 103.00 target, highlighting the distance between clinical promise and regulatory execution.

KOD remains below its yearly high

KOD's USD 94.45 close on Nasdaq on October 2, 2026, was 9.18 percent below its 52-week high of USD 104.00 and far above its 52-week low of USD 10.94. Market capitalization was USD 5.9 billion, with volume of 2,676,503 shares on that session.